Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
1 - 50 out of 244Page size: 50
Sort by: Title

Publications

  1. 56/m mit Rückenschmerzen und Konzentrationsstörungen

    Leypoldt, L. B. & Weisel, K. C., 12.07.2021, In: ONKOLOGE. 2021, 27 supplement issue 1, p. 27-32

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Education

  2. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

    Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L. & Lam, A., 01.2019, In: LEUKEMIA LYMPHOMA. 60, 1, p. 151-162 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

    Weisel, K. C., Scheid, C., Zago, M., Besemer, B., Mai, E. K., Haenel, M., Duerig, J., Munder, M., Lindemann, H-W., Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Salwender, H. & Goldschmidt, H., 08.04.2019, In: BLOOD CANCER J. 9, 4, p. 45

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  4. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

    Mateos, M-V., Weisel, K., Martin, T., Berdeja, J. G., Jakubowiak, A., Stewart, A. K., Jagannath, S., Lin, Y., Diels, J., Ghilotti, F., Thilakarathne, P., Perualila, N. J., Cabrieto, J., Haefliger, B., Erler-Yates, N., Hague, C., Jackson, C. C., Schecter, J. M., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H. & Moreau, P., 01.08.2023, In: HAEMATOLOGICA. 108, 8, p. 2192-2204 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., Scheid, C., Dührsen, U., Lindemann, W., Schmidt-Wolf, I. G. H., Peter, N., Teschendorf, C., Martin, H., Haenel, M., Derigs, H. G., Raab, M. S., Ho, A. D., van de Velde, H., Hose, D., Sonneveld, P. & Goldschmidt, H., 26.01.2012, In: BLOOD. 119, 4, p. 940-8 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    Moreau, P., Dimopoulos, M. A., Richardson, P. G., Siegel, D. S., Cavo, M., Corradini, P., Weisel, K., Delforge, M., O'Gorman, P., Song, K., Chen, C., Bahlis, N., Oriol, A., Hansson, M., Kaiser, M., Anttila, P., Raymakers, R., Joao, C., Cook, G., Sternas, L., Biyukov, T., Slaughter, A., Hong, K., Herring, J., Yu, X., Zaki, M. & San-Miguel, J., 09.2017, In: EUR J HAEMATOL. 99, 3, p. 199-206 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens: entity-specific dividing lines and "pan-leukemia" antigens

    Backert, L., Kowalewski, D. J., Walz, S., Schuster, H., Berlin, C., Neidert, M. C., Schemionek, M., Brümmendorf, T. H., Vucinic, V., Niederwieser, D., Kanz, L., Salih, H. R., Kohlbacher, O., Weisel, K., Rammensee, H-G., Stevanovic, S. & Walz, J. S., 04.07.2017, In: ONCOTARGET. 8, 27, p. 43915-43924 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure

    Davies, F. E., Leleu, X., Vogel, P., Dhanasiri, S., Le Nouveau, P. & Weisel, K., 11.2023, In: CL LYMPH MYELOM LEUK. 23, 11, p. 829-837.e1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

    Weisel, K. C., Dimopoulos, M. A., Moreau, P., Lacy, M. Q., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Knop, S., Yu, X., Hong, K., Sternas, L., Jacques, C., Zaki, M. H. & San Miguel, J., 07.2016, In: HAEMATOLOGICA. 101, 7, p. 872-8 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Rodríguez Otero, P., Towle, K., Cope, S., Caisip, C., Davies, F. E., Delforge, M., Weisel, K., Marshall, T. S., Karampampa, K., Ayers, D., Mojebi, A., Braverman, J., Farrell, J. & Dhanda, D., 2023, In: LEUKEMIA LYMPHOMA. 64, 11, p. 1864-1869 6 p.

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  13. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Leleu, X., Martin, T., Weisel, K., Schjesvold, F., Iida, S., Malavasi, F., Manier, S., Chang-Ki Min, Ocio, E. M., Pawlyn, C., Perrot, A., Quach, H., Richter, J., Spicka, I., Yong, K. & Richardson, P. G., 10.2022, In: ANN HEMATOL. 101, 10, p. 2123-2137 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  14. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

    Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., Khandanpour, C., Seidel-Glaetzer, A., Trautmann-Grill, K., Kortüm, K. M., Müller-Tidow, C., Mechtersheimer, G., Goeppert, B., Stenzinger, A., Weinhold, N., Goldschmidt, H., Weisel, K. C. & Raab, M. S., 06.04.2023, In: BLOOD. 141, 14, p. 1685-1690 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

    Weidmann, E., Hess, G., Chow, K. U., Krause, S. W., Subklewe, M., Kruse, J., Weisel, K. C., Soekler, M., Kim, S-Z., Napieralski, S., Rech, J., Dreyling, M., Jäger, E. & Mitrou, P. S., 03.2010, In: LEUKEMIA LYMPHOMA. 51, 3, p. 447-55 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

    Weisel, K., Doyen, C., Dimopoulos, M., Yee, A., Lahuerta, J. J., Martin, A., Travers, K., Druyts, E., Toor, K., Abildgaard, N., Lu, J., Van Droogenbroeck, J., Geraldes, C., Petrini, M., Voillat, L., Voog, E. & Facon, T., 01.2017, In: LEUKEMIA LYMPHOMA. 58, 1, p. 153-161 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  18. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

    Jansen, L., Merz, M., Engelhardt, M., Weisel, K., Scheid, C., Straka, C., Langer, C., Salwender, H., Einsele, H., Kröger, N., Beelen, D. W., Dreger, P., Goldschmidt, H., Brenner, H. & German National Registry for Stem Cell Transplants (DRST), 10.2020, In: LEUKEMIA LYMPHOMA. 61, 10, p. 2365-2374 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  19. Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma

    Horger, M., Ditt, H., Liao, S., Weisel, K., Fritz, J., Thaiss, W. M., Kaufmann, S., Nikolaou, K. & Kloth, C., 05.2017, In: ACAD RADIOL. 24, 5, p. 623-632 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report

    Cords, L., Schaefers, C., Kamili, A., Hoffmann, C., Cichutek, S., Haag, F., Polywka, S., Bokemeyer, C., Leypoldt, L. B., Alsdorf, W., Schulze zur Wiesch, J. & Weisel, K. C., 28.03.2024, In: HAEMATOLOGICA.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., Usmani, S. Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P. M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R. C., Dettman, E. J., Popat, R., Esposti, S. D., Opalinska, J., Richardson, P. & Cohen, A. D., 02.2020, In: LANCET ONCOL. 21, 2, p. 207-221 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Nooka, A. K., Weisel, K., van de Donk, N. W., Routledge, D., Otero, P. R., Song, K., Quach, H., Callander, N., Minnema, M. C., Trudel, S., Jackson, N. A., Ahlers, C. M., Im, E., Cheng, S., Smith, L., Hareth, N., Ferron-Brady, G., Brouch, M., de Oca, R. M., Paul, S., Holkova, B., Gupta, I., Kremer, B. E. & Richardson, P., 06.2021, In: FUTURE ONCOL. 17, 16, p. 1987-2003 17 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

    Holstein, S. A., Avet-Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., Wallace, P. K., Weisel, K. & McCarthy, P. L., 04.2018, In: BIOL BLOOD MARROW TR. 24, 4, p. 641-648 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  24. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

    Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  25. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

    Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H-W., Merz, M., Hose, D., Jauch, A., Seckinger, A., Luntz, S., Sauer, S., Fuhrmann, S., Brossart, P., Elmaagacli, A., Goerner, M., Bernhard, H., Hoffmann, M., Raab, M. S., Blau, I. W., Hänel, M., Benner, A., Salwender, H. J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 03.2021, In: LEUKEMIA. 35, 3, p. 809-822 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  26. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

    Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Dührsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Merz, M., Baertsch, M-A., Jauch, A., Hose, D., Martin, H., Lindemann, H-W., Blau, I. W., Scheid, C., Weisel, K. C., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 01.2019, In: LEUKEMIA. 33, 1, p. 258-261 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  27. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

    Scheid, C., Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Blau, I. W., Vellenga, E., Weisel, K., Pfreundschuh, M., Jie, K-S., Neben, K., van de Velde, H., Duehrsen, U., Schaafsma, M. R., Lindemann, W., Kersten, M. J., Peter, N., Hänel, M., Croockewit, S., Martin, H., Wittebol, S., Bos, G. M., van Marwijk-Kooy, M., Wijermans, P., Goldschmidt, H. & Lokhorst, H. M., 01.2014, In: HAEMATOLOGICA. 99, 1, p. 148-54 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

    Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., van Marwijk Kooy, M., Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, L., Salwender, H. J. & Sonneveld, P., 02.2018, In: LEUKEMIA. 32, 2, p. 383-390 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial

    Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., Weisel, K. C., Wittebol, S., Bos, G. M. J., Stevens-Kroef, M., Scheid, C., Pfreundschuh, M., Hose, D., Jauch, A., van der Velde, H., Raymakers, R., Schaafsma, M. R., Kersten, M-J., van Marwijk-Kooy, M., Duehrsen, U., Lindemann, W., Wijermans, P. W., Lokhorst, H. M. & Goldschmidt, H. M., 20.08.2012, In: J CLIN ONCOL. 30, 24, p. 2946-55 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  30. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

    Spira, D., Weisel, K., Brodoefel, H., Schulze, M., Kaufmann, S. & Horger, M., 01.2012, In: ACAD RADIOL. 19, 1, p. 89-94 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  31. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

    Weisel, K., Nooka, A. K., Terpos, E., Spencer, A., Goldschmidt, H., Dirnberger, F., DeCosta, L., Yusuf, A. & Kumar, S., 08.2022, In: LEUKEMIA LYMPHOMA. 63, 8, p. 1887-1896 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini

    Kowalewski, D. J., Walz, S., Backert, L., Schuster, H., Kohlbacher, O., Weisel, K., Rittig, S. M., Kanz, L., Salih, H. R., Rammensee, H-G., Stevanović, S. & Stickel, J. S., 08.04.2016, In: BLOOD CANCER J. 6, p. e411

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  33. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A., Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S., Chng, W-J. & ENDEAVOR Investigators, 01.2016, In: LANCET ONCOL. 17, 1, p. 27-38 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

    Weisel, K., Majer, I., DeCosta, L., Oriol, A., Goldschmidt, H., Ludwig, H., Campioni, M., Szabo, Z. & Dimopoulos, M., 01.2020, In: LEUKEMIA LYMPHOMA. 61, 1, p. 37-46 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  35. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

    Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W-J., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N., Aggarwal, S., Feng, S. & Joshua, D., 10.2017, In: LEUKEMIA LYMPHOMA. 58, 10, p. 2501-2504 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    Quach, H., Nooka, A., Samoylova, O., Venner, C. P., Kim, K., Facon, T., Spencer, A., Usmani, S. Z., Grosicki, S., Suzuki, K., Delimpasi, S., Weisel, K., Obreja, M., Zahlten-Kumeli, A. & Mateos, M-V., 08.2021, In: BRIT J HAEMATOL. 194, 4, p. 784-788 5 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  37. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    Dimopoulos, M., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A. & Usmani, S. Z., 18.07.2020, In: LANCET. 396, 10245, p. 186-197 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

    Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W-J., Joshua, D., Weisel, K., Spencer, A., Orlowski, R. Z., Feng, S., Iskander, K. S. & Dimopoulos, M. A., 06.2018, In: LEUKEMIA LYMPHOMA. 59, 6, p. 1364-1374 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

    Chng, W-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D., Palumbo, A., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N., Feng, S., Aggarwal, S. & Hájek, R., 06.2017, In: LEUKEMIA. 31, 6, p. 1368-1374 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  40. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S. & Moreau, P., 10.2017, In: LANCET ONCOL. 18, 10, p. 1327-1337 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

    Pape, L. J., Hambach, J., Gebhardt, A. J., Rissiek, B., Stähler, T., Tode, N., Khan, C., Weisel, K., Adam, G., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 1010270.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

    Kriegsmann, K., Baertsch, M-A., Awwad, M. H. S., Merz, M., Hose, D., Seckinger, A., Jauch, A., Becker, N., Benner, A., Raab, M. S., Hillengass, J., Bertsch, U., Dürig, J., Salwender, H. J., Hänel, M., Fenk, R., Munder, M., Weisel, K., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 29.01.2019, In: BLOOD CANCER J. 9, 2, p. 13

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

    Qian, X., Dimopoulos, M. A., Amatangelo, M., Bjorklund, C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., Sternas, L., Zaki, M., Moreau, P. & Thakurta, A., 02.2019, In: LEUKEMIA LYMPHOMA. 60, 2, p. 462-470 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients

    Ghandili, S., Pfefferle, S., Roedl, K., Sonnemann, P., Karagiannis, P., Boenisch, O., Kluge, S., Schmiedel, S., Ittrich, H., Rohde, H., Lütgehetmann, M., Weisel, K., Bokemeyer, C., Wichmann, D., Fiedler, W., Jarczak, D. & Modemann, F., 08.12.2020, In: Blood Adv. 4, 23, p. 5936-5941 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

    Huhn, S., Weinhold, N., Nickel, J., Pritsch, M., Hielscher, T., Hummel, M., Bertsch, U., Huegle-Doerr, B., Vogel, M., Angermund, R., Hänel, M., Salwender, H. J., Weisel, K., Dürig, J., Görner, M., Kirchner, H., Peter, N., Graeven, U., Lordick, F., Hoffmann, M., Reimer, P., Blau, I. W., Jauch, A., Dembowsky, K., Möhler, T., Wuchter, P. & Goldschmidt, H., 08.2017, In: BONE MARROW TRANSPL. 52, 8, p. 1194-1198 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  46. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era

    Zago, M., Adam, P., Goldschmidt, H., Fend, F., Kanz, L. & Weisel, K., 02.2014, In: CL LYMPH MYELOM LEUK. 14, 1, p. e7-e11

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  47. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

    Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K. L., Hungria, V. T. D. M., Engelhardt, M., Gay, F., Garcia-Feria, A., Oliva, S., Oostvogels, R., Gozzetti, A., Rosenbaum, C. A., Kumar, S. K., Stadtmauer, E., Einsele, H., Beksac, M., Weisel, K. C., Anderson, K. C., Mateos, M-V., Moreau, P., San Miguel, J., Munshi, N. C. & Avet-Loiseau, H., 06.11.2020, In: BLOOD.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  48. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

    Martin, T., Krishnan, A., Yong, K., Weisel, K., Mehra, M., Nair, S., Qi, K., Londhe, A., Diels, J., Crivera, C., Jackson, C. C., Olyslager, Y., Vogel, M., Schecter, J. M., Banerjee, A., Valluri, S., Usmani, S. Z., Berdeja, J. G. & Jagannath, S., 02.2022, In: EJHaem. 3, 1, p. 97-108 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  49. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    Weisel, K., Martin, T., Krishnan, A., Jagannath, S., Londhe, A., Nair, S., Diels, J., Vogel, M., Schecter, J. M., Banerjee, A., Berdeja, J. G., Nesheiwat, T., Garrett, A., Qi, K., Valluri, S., Usmani, S. Z. & Yong, K., 01.2022, In: CLIN DRUG INVEST. 42, 1, p. 29-41 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  50. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Einsele, H., Moreau, P., Bahlis, N., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., Martinez-Lopez, J., Rodríguez-Otero, P., Dytfeld, D., Diels, J., Strulev, V., Haddad, I., Renaud, T., Ammann, E., Cabrieto, J., Perualila, N., Gan, R., Zhang, Y., Parekh, T., Albrecht, C., Weisel, K. & Mateos, M-V., 04.2024, In: ADV THER. 41, 4, p. 1576-1593 18 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 1 2 3 4 5 Next